Cargando…

Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease

Myeloperoxidase (MPO) is a key enzyme in inflammatory and degenerative processes, although conflicting reports have been presented concerning its expression in the brain. We studied the cellular localization of MPO and compared numbers of MPO cells in various brain regions between neurologically hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Gellhaar, Sandra, Sunnemark, Dan, Eriksson, Håkan, Olson, Lars, Galter, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579172/
https://www.ncbi.nlm.nih.gov/pubmed/28466093
http://dx.doi.org/10.1007/s00441-017-2626-8
_version_ 1783260656561029120
author Gellhaar, Sandra
Sunnemark, Dan
Eriksson, Håkan
Olson, Lars
Galter, Dagmar
author_facet Gellhaar, Sandra
Sunnemark, Dan
Eriksson, Håkan
Olson, Lars
Galter, Dagmar
author_sort Gellhaar, Sandra
collection PubMed
description Myeloperoxidase (MPO) is a key enzyme in inflammatory and degenerative processes, although conflicting reports have been presented concerning its expression in the brain. We studied the cellular localization of MPO and compared numbers of MPO cells in various brain regions between neurologically healthy individuals and patients with Parkinson’s disease (PD) or Alzheimer’s disease (AD; n = 10–25). We also investigated two rodent PD models. MPO immunoreactivity (ir) was detected in monocytes, perivascular macrophages and amoeboid microglia in the human brain parenchyma, whereas no co-localization with glial fibrillary acidic protein (GFAP) ir was observed. In the midbrain, caudate and putamen, we found a significant increase of MPO-immunoreactive cells in PD compared with control brains, whereas in the cerebellum, no difference was apparent. MPO ir was detected neither in neurons nor in occasional small beta-amyloid-immunoreactive plaques in PD or control cases. In the frontal cortex of AD patients, we found significantly more MPO-immunoreactive cells compared with control cases, together with intense MPO ir in extracellular plaques. In the hippocampus of several AD cases, MPO-like ir was observed in some pyramidal neurons. Neither rapid dopamine depletion in the rat PD model, nor slow degeneration of dopamine neurons in MitoPark mice induced the expression of MPO ir in any brain region. MPO mRNA was not detectable with radioactive in situ hybridization in any human or rodent brain area, although myeloid cells from bone marrow displayed clear MPO signals. Our results indicate significant increases of MPO-immunoreactive cells in brain regions affected by neurodegeneration in PD and AD, supporting investigations of MPO inhibitors in novel treatment strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00441-017-2626-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5579172
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55791722017-09-18 Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease Gellhaar, Sandra Sunnemark, Dan Eriksson, Håkan Olson, Lars Galter, Dagmar Cell Tissue Res Regular Article Myeloperoxidase (MPO) is a key enzyme in inflammatory and degenerative processes, although conflicting reports have been presented concerning its expression in the brain. We studied the cellular localization of MPO and compared numbers of MPO cells in various brain regions between neurologically healthy individuals and patients with Parkinson’s disease (PD) or Alzheimer’s disease (AD; n = 10–25). We also investigated two rodent PD models. MPO immunoreactivity (ir) was detected in monocytes, perivascular macrophages and amoeboid microglia in the human brain parenchyma, whereas no co-localization with glial fibrillary acidic protein (GFAP) ir was observed. In the midbrain, caudate and putamen, we found a significant increase of MPO-immunoreactive cells in PD compared with control brains, whereas in the cerebellum, no difference was apparent. MPO ir was detected neither in neurons nor in occasional small beta-amyloid-immunoreactive plaques in PD or control cases. In the frontal cortex of AD patients, we found significantly more MPO-immunoreactive cells compared with control cases, together with intense MPO ir in extracellular plaques. In the hippocampus of several AD cases, MPO-like ir was observed in some pyramidal neurons. Neither rapid dopamine depletion in the rat PD model, nor slow degeneration of dopamine neurons in MitoPark mice induced the expression of MPO ir in any brain region. MPO mRNA was not detectable with radioactive in situ hybridization in any human or rodent brain area, although myeloid cells from bone marrow displayed clear MPO signals. Our results indicate significant increases of MPO-immunoreactive cells in brain regions affected by neurodegeneration in PD and AD, supporting investigations of MPO inhibitors in novel treatment strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00441-017-2626-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-05-02 2017 /pmc/articles/PMC5579172/ /pubmed/28466093 http://dx.doi.org/10.1007/s00441-017-2626-8 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
spellingShingle Regular Article
Gellhaar, Sandra
Sunnemark, Dan
Eriksson, Håkan
Olson, Lars
Galter, Dagmar
Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease
title Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease
title_full Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease
title_fullStr Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease
title_full_unstemmed Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease
title_short Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease
title_sort myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in parkinson’s and alzheimer’s disease
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579172/
https://www.ncbi.nlm.nih.gov/pubmed/28466093
http://dx.doi.org/10.1007/s00441-017-2626-8
work_keys_str_mv AT gellhaarsandra myeloperoxidaseimmunoreactivecellsaresignificantlyincreasedinbrainareasaffectedbyneurodegenerationinparkinsonsandalzheimersdisease
AT sunnemarkdan myeloperoxidaseimmunoreactivecellsaresignificantlyincreasedinbrainareasaffectedbyneurodegenerationinparkinsonsandalzheimersdisease
AT erikssonhakan myeloperoxidaseimmunoreactivecellsaresignificantlyincreasedinbrainareasaffectedbyneurodegenerationinparkinsonsandalzheimersdisease
AT olsonlars myeloperoxidaseimmunoreactivecellsaresignificantlyincreasedinbrainareasaffectedbyneurodegenerationinparkinsonsandalzheimersdisease
AT galterdagmar myeloperoxidaseimmunoreactivecellsaresignificantlyincreasedinbrainareasaffectedbyneurodegenerationinparkinsonsandalzheimersdisease